Member Info for Dibs61

I can dummy sell 250k @ .775 which is the mid so maybe we'll be in the move soon. 2017 finally a year of transformation for HDD. Good chance imv.

Skiing holidays? A rather flippant reply if I may say so. No, it's not a case of 'getting around to it' in terms of news, if there is market sensitive information out there they are obliged to report it within a given time limit. I know this company pretty well and if I recall correctly been following it longer than your good self. It is a matter of concern that with supposedly so much corporate and operational activity going on there is a radio silence. People are waiting on the sidelines with good reason.

I really would've expected them to confirm that A6 flow testing had commenced. Wouldn't you? BTW I'm still holding but am getting a bit concerned. No news is rarely good news on AIM.

Go into winter hibernation? Not a word for over two months with so much going on.

The Kalevala or The Kalewala (/ˌkɑːləˈvɑːlə/;[1] Finnish: [ˈkɑle̞ʋɑlɑ]) is a 19th-century work of epic poetry compiled by Elias Lönnrot from Karelian and Finnish oral folklore and mythology.[2] Folklore and mythology eh? Very appropriate!

unv - good research mate thanks

Welcome! Remember you from RENE in recent times. I've been building a holding here over some time and stock had previously been on my watchlist for a very long time (with a few mainly modestly successful previous 'trades'. I like this company a lot. Transformative products can take a long time to get to market, if they ever do. ODX have two such projects. One is now 'live' but very early days and with the prospect of a significant deal. The other is a potentially mind blowing prospect on POC HIV tests. CD4, we think, is now in field trials - last testing stage before commercialisation. It has USP over potential competitors. The company has received substantial grants from Scottish Enterprise. Also, check out the shareholder roster. For such a small company it's impressive. Note also a chap called Richard Sneller who knows a thing or two about investing in emerging markets. Big bull point for me is he has been loading up here like there's no tomorrow. Not a name like Woodford but he has an impressive track record. Interestingly for a micro company this has good support from institutions but virtually unknown by disinterested PI community. This is NOT an AIM casino outfit. This is a serious business - consistently making profit - on the brink IMO of a new era of sharply better prospects. DYOR

Management are looking at ways to achieve an accelerated growth strategy. At the moment the market rates it low,y against its peer group. Harsh, but that maybe because, although profitable it's considered a plodder. The Allersys deal, whatever it may be could be the key to unlocking value AND achieving that coveted faster growth. I think we have what Immunodiagnostic wants now so we must be in a decent position. And when you consider we are by no means a one trick pony with three distinct business divisions the future is very bright. 2017 = Year of the Rerating

Very good performance I would say against the current gold price and notably strong today. Interesting

NOT good. Not good at all.

Yes. And note how they held the price @ 18p. Mates rates. If you tried to buy these quantities in the open open market you'd have paid way more.

Certainly nothing comparable either on the market or at this stage of development. Definitely not. Indeed two of Omegas competitors products have fallen out of development this year.

I also understand from a poster on ADVFN that Omega have been posting on Twitter that the CD4 test being used in South Africa. Could this be part of the scheduled field trials. South Africa is the biggest HIV market in the world. Exciting times for HIV sufferers in the underdeveloped world and for us.

Good post. I agree with your points about AIM. I believe we have timed this right. Some exciting developments to come in 2017 and hopefully very shortly in terms of Allersys.

I think that would clear any last vestige of uncertainty regarding the final phase of the CD4 Project - funding commercialisation costs. It is clear that Allersys, one way or another, is key to making this happen. No question 30p on the board if we get a sniff of that happening. And that's just to put us in base camp.

Head of Global Emerging Market Equities at Baillie Gifford personally has a stake of 10.5% here. Just saying.

Institutional buying to me. But if not, someone is buying in decent quantities and important to emphasise this is unusual trading behaviour here but welcome

In fact a number of larger size buys (relative to what is 'normal' here) are coming in now.

I meant 2017 not 2917! Sometimes it feels like you're waiting that long on aim!

Nice delayed buy. With CD4 HIV test commercialisation next year and the impending developments on the new Allerysys range I reckon this is going to be a top performer in 2917. Currently very lowly rated in its peer group but with plans for accelerated growth and undervalued on NAV. One of the best companies on AIM IMHO